论文部分内容阅读
多发性骨髓瘤(MM)是一种以骨髓中积聚浆细胞为特征,且难以治愈的恶性肿瘤。既往应用的MP(马法仑、泼尼松),M2(环磷酰胺、卡氮芥、泼尼松、马法仑、长春新碱),VAD(长春新碱、阿霉素、地塞米松)等化疗方案,虽然可取得一定的疗效,但完全缓解(CR)率不高,缓解时间不长〔1〕。近些年,来那度胺和硼替佐米等新药的问世使MM的治疗发展迅速〔2〕。但由于新药费用昂贵,目前我国大部分MM患者难以承受。而沙利度胺作为一种抗血管
Multiple myeloma (MM) is a malignant tumor characterized by accumulation of plasma cells in the bone marrow that is difficult to cure. Previously used MPs (melphalan, prednisone), M2 (cyclophosphamide, carmustine, prednisone, melphalan, vincristine), VAD (vincristine, doxorubicin, ) And other chemotherapy regimens, although a certain effect can be achieved, but the complete remission (CR) rate is not high, the relief time is not long 〔1〕. In recent years, the advent of new drugs such as lenalidomide and bortezomib have led to the rapid development of MM therapy [2]. However, due to the high cost of new drugs, most MM patients in China are unbearable. Thalidomide acts as an anti-angiogenic agent